Gastroesophageal Reflux Disease Clinical Trial
Official title:
CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD
| NCT number | NCT00325676 |
| Other study ID # | BY1023/M3-342 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 4 |
| First received | May 12, 2006 |
| Last updated | May 4, 2012 |
| Start date | June 2006 |
| Verified date | June 2007 |
| Source | Takeda |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Germany: Federal Institute for Drugs and Medical Devices |
| Study type | Interventional |
The aim of this study is to evaluate the complete remission rates, endoscopic relapses, study discontinuation rates, and quality of life parameters in patients with erosive GERD. The study duration consists of a treatment period up to 16 weeks according to the classical healing concept or the complete remission concept. During this period, the patients will receive pantoprazole (tablet) at one dose level once daily. The following observational phase lasts up to 6 months. The study will provide further data on efficacy, safety, and tolerability of pantoprazole.
| Status | Completed |
| Enrollment | 639 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Main Inclusion Criteria: - Written informed consent - Endoscopically confirmed GERD (Los Angeles classification A-D) - Patients whose compliance is expected to be high with respect to the completion of the questionnaires Main Exclusion Criteria: - Other gastrointestinal diseases - Severe concomitant diseases - Proton pump inhibitors (PPIs) during last 14 days before start - H2 receptor antagonists, prokinetics during last 7 days before study start - Helicobacter pylori (H. pylori) eradication during last 28 days before study start |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Brazil | Altana Pharma/Nycomed | Belo Horizonte-MG | |
| Brazil | Altana Pharma/Nycomed | Blumenau - SC | |
| Brazil | Altana Pharma/Nycomed | Botucatu - SP | |
| Brazil | Altana Pharma/Nycomed | Campinas - Sao Paulo | |
| Brazil | Altana Pharma/Nycomed | Campinas - SP | |
| Brazil | Altana Pharma/Nycomed | Curitiba - PR | |
| Brazil | Altana Pharma/Nycomed | Ilha do Fundao - Rio de Janeiro - RJ | |
| Brazil | Altana Pharma/Nycomed | Pinheiros Sao Paulo - SP | |
| Brazil | Altana Pharma/Nycomed | Porto Alegre - RS | |
| Brazil | Altana Pharma/Nycomed | Porto Alegre-RS | |
| Brazil | Altana Pharma/Nycomed | Porto Alegre-RS | |
| Brazil | Altana Pharma/Nycomed | Ribeirao Preto-SP | |
| Brazil | Altana Pharma/Nycomed | Salvador-BA | |
| Brazil | Altana Pharma/Nycomed | Sao Paulo | |
| Germany | Altana Pharma/Nycomed | Bad Schwalbach | |
| Germany | Altana Pharma/Nycomed | Burg | |
| Germany | Altana Pharma/Nycomed | Gardelegen | |
| Germany | Altana Pharma/Nycomed | Königstein | |
| Germany | Altana Pharma/Nycomed | Lübeck | |
| Germany | Altana Pharma/Nycomed | Lüdenscheid | |
| Germany | Altana Pharma/Nycomed | Lütjenburg | |
| Germany | Altana Pharma/Nycomed | Nieder-Olm | |
| Germany | Altana Pharma/Nycomed | Oelde | |
| Germany | Altana Pharma/Nycomed | Wiesbaden | |
| Germany | Altana Pharma/Nycomed | Wolmirstedt | |
| Poland | Altana Pharma/Nycomed | Bydgoszcz | |
| Poland | Altana Pharma/Nycomed | Inowroclaw | |
| Poland | Altana Pharma/Nycomed | Poznan | |
| Poland | Altana Pharma/Nycomed | Siemianowice Slaskie | |
| Poland | Altana Pharma/Nycomed | Torun | |
| Poland | Altana Pharma/Nycomed | Tychy | |
| South Africa | Altana Pharma/Nycomed | Amanzimtoti | |
| South Africa | Altana Pharma/Nycomed | Berea, Durban | |
| South Africa | Altana Pharma/Nycomed | Bloemfontein | |
| South Africa | Altana Pharma/Nycomed | Bloemfontein | |
| South Africa | Altana Pharma/Nycomed | Cape Town | |
| South Africa | Altana Pharma/Nycomed | Durban | |
| South Africa | Altana Pharma/Nycomed | Goodwood | |
| South Africa | Altana Pharma/Nycomed | Johannesburg | |
| South Africa | Altana Pharma/Nycomed | Overport, Durban | |
| South Africa | Altana Pharma/Nycomed | Panorama | |
| South Africa | Altana Pharma/Nycomed | Pinetown | |
| South Africa | Altana Pharma/Nycomed | Port Elizabeth | |
| South Africa | Altana Pharma/Nycomed | Pretoria | |
| South Africa | Altana Pharma/Nycomed | Somerset-West |
| Lead Sponsor | Collaborator |
|---|---|
| Takeda |
Brazil, Germany, Poland, South Africa,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | time to endoscopic relapse and/or unwillingness to continue due to GERD related symptoms | |||
| Secondary | further efficacy criteria | |||
| Secondary | safety |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02135107 -
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
|
Phase 3 | |
| Completed |
NCT01432392 -
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease
|
N/A | |
| Recruiting |
NCT01249482 -
Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
|
N/A | |
| Completed |
NCT01200550 -
The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients
|
N/A | |
| Completed |
NCT01578642 -
Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease
|
Phase 2 | |
| Unknown status |
NCT01128608 -
The Effect of High PCO2 Solution on Esophageal Acid Sensation
|
N/A | |
| Completed |
NCT00978016 -
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
|
Phase 2 | |
| Completed |
NCT00998244 -
Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease
|
N/A | |
| Completed |
NCT00768443 -
Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)
|
N/A | |
| Completed |
NCT00768196 -
Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients
|
N/A | |
| Recruiting |
NCT00498082 -
Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease
|
N/A | |
| Completed |
NCT00886197 -
Diagnostic Efficacy of Narrow Band Imaging in Patients With Gastroesophageal Reflux Disease
|
N/A | |
| Completed |
NCT00378898 -
Feasibility of Placing Bravo PH Capsule in Proximal Esophagus
|
N/A | |
| Completed |
NCT00507377 -
Foreshortened Esophagus and Its Surgical Therapy
|
||
| Completed |
NCT00217347 -
Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy
|
N/A | |
| Completed |
NCT00165022 -
Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population
|
N/A | |
| Completed |
NCT00625495 -
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
|
Phase 4 | |
| Completed |
NCT00214552 -
Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
|
Phase 3 | |
| Completed |
NCT00618150 -
Patient Education in Gastroesophageal Reflux Disease
|
N/A | |
| Completed |
NCT03299985 -
Diaphragmatic Myofascial Release in Gastroesophageal Reflux Disease
|
N/A |